PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) issued its earnings results on Wednesday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.17, Zacks reports.

PolyPid Trading Down 2.7%

PYPD traded down $0.10 during trading on Wednesday, reaching $3.66. The stock had a trading volume of 16,859 shares, compared to its average volume of 175,845. The company has a market capitalization of $58.18 million, a price-to-earnings ratio of -0.95 and a beta of 1.53. PolyPid has a one year low of $2.30 and a one year high of $3.93. The stock’s 50 day moving average is $3.48 and its two-hundred day moving average is $3.34.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of PolyPid from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PolyPid in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of PolyPid in a report on Wednesday, August 13th. Craig Hallum reiterated a “buy” rating and set a $13.00 target price (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th. Finally, Roth Capital restated a “buy” rating on shares of PolyPid in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, PolyPid currently has a consensus rating of “Moderate Buy” and an average price target of $12.40.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.